AS ONE (7476) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
31 Jul, 2026Executive summary
Net sales reached ¥30,002 million, up 17.0% year-over-year, and operating profit rose 27.3% to ¥3,980 million, both marking record highs for Q1, driven by robust demand in research, industrial, and medical instruments.
Profit attributable to owners of parent increased 25.2% to ¥2,853 million, with all major profit metrics achieving record levels.
Growth was supported by strong R&D activity, increased demand for plastic consumables, and expanded e-commerce and consolidated purchasing by large customers.
Financial highlights
Gross profit increased 17.6% year-over-year to ¥9,269 million, with a gross profit margin of 30.9%, up 0.2 points.
Operating profit margin improved to 13.3%, up 1.1 points year-over-year.
EPS rose 25.9% to ¥40.04.
SG&A expenses increased 11.3% year-over-year to ¥5,288 million, but the SG&A ratio improved by 0.9 points to 17.6% due to efficient cost management.
Comprehensive income increased 35.8% year-over-year to ¥4,445 million.
Outlook and guidance
Full-year forecast for FY ending March 31, 2027: net sales ¥117,850 million (+6.5% YoY), operating profit ¥12,900 million (+0.5%), ordinary profit ¥13,350 million (+0.9%), profit attributable to owners of parent ¥8,970 million (−2.3%), EPS ¥125.86.
Dividend per share forecast at ¥66.00.
No changes to initial guidance; the outlook does not factor in the ongoing Middle East situation.
Extraordinary loss of ¥244 million expected due to demolition and logistics hub consolidation.
Latest events from AS ONE
- Steady growth driven by a vast product range, digitalization, and expanding service offerings.7476
Corporate presentation31 Jul 2026 - Record sales and profits, robust e-commerce growth, and strong shareholder returns continue.7476
Q4 202613 May 2026 - Strong profit and sales growth driven by e-commerce and industrial segments; outlook steady.7476
Q3 202630 Jan 2026 - Record profit growth and margin gains offset medical sector weakness; profit outlook raised.7476
Q2 202631 Oct 2025 - Strong profit and sales growth driven by scientific and industrial demand; outlook maintained.7476
Q1 202631 Jul 2025 - Record sales and profit growth driven by e-commerce and product expansion.7476
Q2 202513 Jun 2025 - Record sales and profit growth, led by e-commerce, offset by lower gross margin.7476
Q1 202513 Jun 2025 - Record sales, profit, and dividend growth with strong EC momentum and positive outlook.7476
Q4 20256 Jun 2025 - Net sales and profits rose over 10% year-on-year, with robust e-commerce and digital growth.7476
Q3 20255 Jun 2025